Clomiphene: A Literature Course on What the Published Studies Report

This course summarises what the published literature says about clomiphene, organised into six modules. It describes studies, populations and endpoints as researchers reported them, and it does not recommend any use, dose or protocol. This page is for educational purposes only and is not medical advice; consult a licensed physician about any medical question or treatment decision.

Module 1: What Clomiphene Is and How It Has Been Studied

Clomiphene, usually formulated as clomiphene citrate, is a small-molecule selective estrogen receptor modulator (SERM) of the triphenylethylene chemical class. It is administered orally in tablet form and exists as a mixture of two geometric isomers, commonly named enclomiphene (the trans isomer) and zuclomiphene (the cis isomer). A 2024 review in Translational Andrology and Urology examined both clomiphene citrate and the isolated enclomiphene isomer in hypogonadal men and discussed their reported safety and efficacy profiles side by side (https://pubmed.ncbi.nlm.nih.gov/39434750/).

Is clomiphene a peptide?

No. Peptides are chains of amino acids; clomiphene is a synthetic non-steroidal organic molecule and shares no structural relationship with peptide hormones such as gonadorelin or hCG. It appears alongside peptides in some hormone-research discussions only because the published literature describes it acting on the same hypothalamic–pituitary–gonadal axis that peptide secretagogues are studied against, as reviewed in hypogonadal men (https://pubmed.ncbi.nlm.nih.gov/39434750/).

How it has been studied

The literature base spans several distinct research traditions:

• Female reproductive medicine: ovulation induction and prediction of response, including a 2019 study that examined predictors of responsiveness to clomiphene citrate in infertile women with polycystic ovary syndrome (https://pubmed.ncbi.nlm.nih.gov/31423417/).
• Male infertility and hypogonadism: pooled analyses such as a 2023 systematic review and meta-analysis of clomiphene citrate for male infertility (https://pubmed.ncbi.nlm.nih.gov/36680549/).
• Case reports and pharmacovigilance-style reports describing individual adverse events, discussed in Module 4.
• Analytical chemistry and anti-doping science, including a 2023 report identifying and synthesising (Z)-3'-hydroxy clomiphene as a potential doping-relevant metabolite (https://pubmed.ncbi.nlm.nih.gov/37580503/).

Limits of the evidence in Module 1

Definitions and chemistry are settled, but the study base is uneven: female ovulation-induction research is far older and larger than the male-hormone literature, and several of the verified reports below are single-patient case reports that describe an event without establishing how often it occurs.

Module 2: Mechanism as Described in the Literature

Reviews describe clomiphene as competing with estradiol at estrogen receptors in the hypothalamus and pituitary. Because estradiol normally suppresses gonadotropin output, blocking that signal is described as increasing pulsatile gonadotropin-releasing hormone and downstream luteinising hormone and follicle-stimulating hormone secretion. In hypogonadal men, the 2024 review framed this endogenous-stimulation mechanism as the basis for clomiphene and enclomiphene raising testosterone without exogenous androgen administration (https://pubmed.ncbi.nlm.nih.gov/39434750/). In women with anovulatory infertility, the same central mechanism is described as driving follicular recruitment, and a 2019 study analysed which baseline characteristics predicted whether infertile women with PCOS responded to clomiphene citrate at all (https://pubmed.ncbi.nlm.nih.gov/31423417/).

Mechanism is not uniformly agonist or antagonist

Because SERM activity is tissue-dependent, mechanistic effects reported in one tissue do not transfer to another. A 2018 study in European Journal of Obstetrics, Gynecology, and Reproductive Biology reported that clomiphene citrate increased nitric oxide and interleukin-10 and reduced matrix metalloproteinase-9 in women with polycystic ovary syndrome, describing vascular and inflammatory markers rather than gonadotropins (https://pubmed.ncbi.nlm.nih.gov/29908374/). Separately, a 2017 report in Arquivos de Neuro-Psiquiatria described clomiphene treatment as possibly effective in refractory episodic and chronic cluster headache, a hypothalamically framed indication outside reproductive endocrinology (https://pubmed.ncbi.nlm.nih.gov/28977141/).

Limits of the evidence in Module 2

Mechanistic descriptions in these papers are largely inferred from hormone and biomarker measurements in patients rather than from receptor-occupancy experiments. The biomarker changes reported in PCOS (https://pubmed.ncbi.nlm.nih.gov/29908374/) were not linked in that report to clinical endpoints, and no verified paper here mapped isomer-specific receptor behaviour in humans.

Module 3: Reported Outcomes by Study

The table below summarises what each verified study examined and what researchers reported. No dose figures are listed because the verified source set does not support stating them.

The ceiling-effect finding

One of the more specific observations in this set is dose-related without being a dosing instruction: researchers reported a ceiling effect of clomiphene citrate on the testosterone-to-estradiol ratio in eugonadal infertile men, meaning further increases in exposure did not continue to shift that ratio (https://pubmed.ncbi.nlm.nih.gov/35100304/). That observation applies only to the endpoint the study measured in the population it enrolled.

Limits of the evidence in Module 3

Hormonal endpoints such as serum testosterone or the testosterone-to-estradiol ratio are surrogate measures; the verified male-fertility literature does not establish live-birth outcomes, and the 2023 meta-analysis itself pooled heterogeneous studies (https://pubmed.ncbi.nlm.nih.gov/36680549/). The cluster-headache report (https://pubmed.ncbi.nlm.nih.gov/28977141/) was not a randomised controlled trial, and none of these results should be read as a promise of benefit for any individual.

Clomiphene Side Effects: What Studies Report

Adverse-event information in the verified literature comes from two sources: cohort and review-level safety appraisals, and individual case reports of uncommon events.

Cohort and review-level safety data

A 2019 cohort in The Journal of Urology assessed long-term safety alongside efficacy of clomiphene citrate for the treatment of hypogonadism, making it the longest-horizon safety document in this set (https://pubmed.ncbi.nlm.nih.gov/31216250/). The 2024 review of hypogonadal men likewise evaluated safety as a co-primary theme when comparing enclomiphene with clomiphene (https://pubmed.ncbi.nlm.nih.gov/39434750/), and the 2023 systematic review and meta-analysis in male infertility considered tolerability as part of its pooled appraisal (https://pubmed.ncbi.nlm.nih.gov/36680549/).

Published case reports

• Thromboembolism: a 2021 case report in Journal of Community Hospital Internal Medicine Perspectives described clomiphene-induced pulmonary embolism in a single patient (https://pubmed.ncbi.nlm.nih.gov/33889332/).
• Severe hypertriglyceridemia: a 2009 report in Fertility and Sterility described clomiphene citrate-induced severe hypertriglyceridemia (https://pubmed.ncbi.nlm.nih.gov/19380127/).
• Visual and optic events: a 2021 case report in International Journal of Reproductive Biomedicine described presumed clomiphene-induced optic neuropathy (https://pubmed.ncbi.nlm.nih.gov/34278201/).

Limits of the evidence in Module 4

Case reports describe temporal association, not proven causation, and a single report cannot indicate incidence; the optic neuropathy report explicitly framed the association as presumed (https://pubmed.ncbi.nlm.nih.gov/34278201/). Cohort safety data in men were collected in clinical settings with monitoring (https://pubmed.ncbi.nlm.nih.gov/31216250/), so they do not describe unsupervised exposure. Rare events, long-latency events and events in populations not enrolled remain uncharacterised in this set.

Module 5: Pharmacokinetics and Metabolite Data

The verified papers do not include a dedicated human pharmacokinetic study with absorption, distribution or half-life parameters. What they do provide is metabolite and detection chemistry. A 2023 report in Rapid Communications in Mass Spectrometry identified and synthesised (Z)-3'-hydroxy clomiphene as a new potential doping-relevant metabolite of clomiphene (https://pubmed.ncbi.nlm.nih.gov/37580503/). A 2022 study in Analytica Chimica Acta assessed human urinary clomiphene metabolites after consumption of eggs from clomiphene-treated laying hens using chromatographic-mass spectrometric approaches (https://pubmed.ncbi.nlm.nih.gov/35341524/).

The closest thing to exposure-response information in this set is pharmacodynamic rather than pharmacokinetic: researchers described a ceiling effect on the testosterone-to-estradiol ratio in eugonadal infertile men, indicating that the measured hormonal response did not scale indefinitely with exposure (https://pubmed.ncbi.nlm.nih.gov/35100304/).

Limits of the evidence in Module 5

No verified paper here reported plasma concentration curves, isomer-specific elimination half-lives, drug–drug interaction data or renal and hepatic adjustment data. The analytical papers describe metabolite identification and urinary detection in the contexts they studied (https://pubmed.ncbi.nlm.nih.gov/37580503/, https://pubmed.ncbi.nlm.nih.gov/35341524/) and nothing beyond those contexts should be inferred from them.

Module 6: Regulatory Status

Stated factually, and not as legal advice:

• Approved products. Clomiphene citrate is an approved prescription oral drug in the United States and many other jurisdictions for ovulation induction in selected anovulatory women, marketed historically under brand names including Clomid and Serophene. It is a small-molecule drug regulated as such, not a dietary supplement and not a peptide product.
• Off-label use in men. Use of clomiphene citrate in men for hypogonadism or infertility is not an approved indication in the United States; it is described in the literature as off-label, which is why cohort and review evidence in men has been published as investigational or clinical-practice experience (https://pubmed.ncbi.nlm.nih.gov/31216250/, https://pubmed.ncbi.nlm.nih.gov/39434750/).
• Enclomiphene. The isolated trans isomer has been studied and reviewed in hypogonadal men (https://pubmed.ncbi.nlm.nih.gov/39434750/) but is not an FDA-approved finished drug product in the United States.
• Research-use-only material. Chemical-grade clomiphene sold as "research use only" is not manufactured or released as a medicine, carries no therapeutic labelling, and is not intended for human or veterinary administration.
• Compounding. In the United States, compounded preparations may be prepared by state-licensed 503A pharmacies for an identified patient pursuant to a prescription, or by registered 503B outsourcing facilities; compounded preparations are not FDA-approved products and are not reviewed for safety, efficacy or manufacturing quality in the way approved drugs are.
• Anti-doping context. Clomiphene is a target analyte in sports drug testing, which is the framing of the metabolite identification work (https://pubmed.ncbi.nlm.nih.gov/37580503/) and of the urinary metabolite study conducted after consumption of eggs from clomiphene-treated laying hens (https://pubmed.ncbi.nlm.nih.gov/35341524/).

Limits of the evidence in Module 6

Regulatory status is jurisdiction-specific and changes over time, and none of the verified papers were regulatory documents. This section is general information, not legal advice; licensing, prescribing and compounding rules should be checked against current primary sources in the relevant jurisdiction.

What the Studies Did Not Test

Across the verified literature, several questions remain open:

1. Healthy, non-clinical use. The enrolled populations were infertile or hypogonadal patients, or women with PCOS (https://pubmed.ncbi.nlm.nih.gov/31423417/); no verified study examined use by healthy people without a diagnosed condition.
2. Head-to-head clinical superiority. The 2024 review compared enclomiphene and clomiphene narratively in hypogonadal men (https://pubmed.ncbi.nlm.nih.gov/39434750/) rather than reporting a definitive randomised comparison.
3. Hard reproductive outcomes in men. The 2023 meta-analysis in male infertility focused on pooled measurable parameters (https://pubmed.ncbi.nlm.nih.gov/36680549/); long-horizon fertility and offspring outcomes were not the subject of any verified paper here.
4. Incidence of the rare events. Pulmonary embolism (https://pubmed.ncbi.nlm.nih.gov/33889332/) and severe hypertriglyceridemia (https://pubmed.ncbi.nlm.nih.gov/19380127/) were reported as individual cases, not with denominators.
5. Combination or sequential regimens. No verified study in this set evaluated clomiphene alongside other hormonal agents, and this course gives no timing or combination information.
6. Formal pharmacokinetics. As noted in Module 5, concentration-time data were absent from the verified set.

Readers comparing these modules should treat the surrogate endpoints, the case reports and the analytical chemistry as separate bodies of evidence that answer different questions. This page remains educational only and is not medical advice; a licensed physician is the appropriate source for individual questions.

References

• Clomiphene citrate for male infertility: A systematic review and meta-analysis (Andrology, 2023)
• Safety and efficacy of enclomiphene and clomiphene for hypogonadal men (Translational Andrology and Urology, 2024)
• Long-Term Safety and Efficacy of Clomiphene Citrate for the Treatment of Hypogonadism (The Journal of Urology, 2019)
• Ceiling effect of clomiphene citrate on the testosterone to estradiol ratio in eugonadal infertile men (PLoS One, 2022)
• Clomiphene citrate increases nitric oxide, interleukin-10 and reduces matrix metalloproteinase-9 in women with polycystic ovary syndrome (European Journal of Obstetrics, Gynecology, and Reproductive Biology, 2018)
• Prediction of Responsiveness to Clomiphene Citrate in Infertile Women with PCOS (Journal of Reproduction & Infertility, 2019)
• Clomiphene treatment may be effective in refractory episodic and chronic cluster headache (Arquivos de Neuro-Psiquiatria, 2017)
• Clomiphene-induced pulmonary embolism (Journal of Community Hospital Internal Medicine Perspectives, 2021)
• Clomiphene citrate-induced severe hypertriglyceridemia (Fertility and Sterility, 2009)
• Presumed clomiphene-induced optic neuropathy: A case report (International Journal of Reproductive Biomedicine, 2021)
• Identification and synthesis of (Z)-3'-hydroxy clomiphene as a new potential doping-relevant metabolite of clomiphene (Rapid Communications in Mass Spectrometry, 2023)
• Assessing human urinary clomiphene metabolites after consumption of eggs from clomiphene-treated laying hens using chromatographic-mass spectrometric approaches (Analytica Chimica Acta, 2022)